Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9NYK1
UPID:
TLR7_HUMAN
Alternative names:
-
Alternative UPACC:
Q9NYK1; D1CS69; Q9NR98
Background:
Toll-like receptor 7 (TLR7) is a pivotal endosomal receptor in the immune system, recognizing uridine-rich ssRNAs from viruses or guanosine analogs. This recognition triggers TLR7 dimerization, leading to the formation of the Myddosome signaling complex, activating NF-kappa-B and IRF7, and ultimately inducing pro-inflammatory cytokines and interferons.
Therapeutic significance:
TLR7's role in diseases such as Immunodeficiency 74, COVID19-related, X-linked, and Systemic lupus erythematosus 17, underscores its potential as a target for therapeutic intervention. Understanding TLR7's function could pave the way for novel treatments for these immune-related conditions.